hyperaldosteronism: Overproduction of aldosterone by the adrenal glands, which may lead to hypokalemia and/or hypernatremia. [ NCIT:P378 ]
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
404 |
4. Check minimum number of eventsNone |
404 |
5. Include endpointsNone |
404 |
6. Filter based on genotype QC (FinnGen only) |
404 |
Control definitions (FinnGen only)
- Control exclude
- E4_ENDOGLAND
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF6
- Parent code in ICD-10
- E20-E35
- Name in latin
- Syndroma Cushing
Similar endpoints
↥List of similar endpoints to
Cushing syndrome
based on the number of shared cases.
Similar with more cases:
- Disorders of other endocrine glands
- Endocrine, nutritional and metabolic diseases
- Any event in hilmo or specialist outpatient
Similar with less cases:
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 2517 | 1702 | 780 |
| Only index persons | 1932 | 1354 | 578 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.04 | 0.05 | 0.02 |
| Only index persons | 0.04 | 0.05 | 0.02 |
| Median age at first event (years) | |||
| Whole population | 52.43 | 51.81 | 53.66 |
| Only index persons | 48.38 | 47.55 | 50.32 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 404 | 283 | 121 |
| Unadjusted period prevalence (%) | 0.08 | 0.10 | 0.05 |
| Median age at first event (years) | 51.12 | 47.52 | 59.54 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 360
- Matched controls
- 3599
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
H02AB09
ATC
hydrocortisone; systemic
118.2
133.4
139
19
E24.9
ICD-10 Finland
Cushing syndrome, unspecified
+∞
130.3
117
*
E24.0
ICD-10 Finland
Pituitary-dependent Cushing disease
+∞
107.9
98
*
E24.8
ICD-10 Finland
Other Cushing syndrome
+∞
96.3
88
*
D35.0
ICD-10 Finland
Benign neoplasm: Adrenal gland
68.8
63.6
72
13
D35.2
ICD-10 Finland
Benign neoplasm: Pituitary gland
215.6
54.6
55
*
BCA31
NOMESCO Finland
Endoscopic unilateral adrenalectomy
275.9
48.3
48
*
AA4CG
NOMESCO Finland
Extensive MRI examination of sella turcica with high intensity magnet
269.3
47.2
47
*
105
Kela drug reimbursment
Adrenal cortical hypofunction
+∞
44.7
42
*
AAE10
NOMESCO Finland
Transsphenoidal total or partial excision of intracranial lesion
483.2
44.2
43
*
D44.1
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Adrenal gland
100.0
40.8
44
5
E24.2
ICD-10 Finland
Drug-induced Cushing syndrome
+∞
40.4
38
*
H02AA02
ATC
fludrocortisone; oral
94.9
38.7
42
5
Z03.80
ICD-10 Finland
Observation for other suspected diseases and conditions
14.4
36.4
63
52
E27.4
ICD-10 Finland
Other and unspecified adrenocortical insufficiency
+∞
29.6
28
*
V04CD01
ATC
metyrapone; oral
+∞
29.6
28
*
25800
ICD-8 Finland
Polyglandular dysfunction and other diseases of endocrine glands, Cushing's syndrome
+∞
28.5
27
*
E89.6
ICD-10 Finland
Postprocedural adrenocortical(-medullary) hypofunction
+∞
28.5
27
*
C03DA01
ATC
spironolactone; oral
6.0
27.6
83
171
E24.3
ICD-10 Finland
Ectopic ACTH syndrome
+∞
26.4
25
*
NK6QA
NOMESCO Finland
Measurement of bone density from tow or more locations with X-ray
6.8
24.8
66
115
101
Kela drug reimbursment
Anterior pituitary hypofunction
+∞
23.2
22
*
A10AE04
ATC
insulin glargine; parenteral
5.4
21.6
69
151
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
3.0
20.2
153
704
2550A
ICD-9 Finland
Disorders of adrenal glands, Cushing's syndrome[SDR CUSHING E HYPERPLASIA GLANDULAE SUPRARENALI]
+∞
20.0
19
*
C08CA01
ATC
amlodipine; oral
3.0
19.8
153
709
BCA30
NOMESCO Finland
Unilateral adrenalectomy
211.1
19.8
20
*
GD1AA
NOMESCO Finland
Thorax X-ray examination
2.8
18.4
184
991
103
Kela drug reimbursment
Diabetes, insulin-treated
3.0
18.1
131
574
2550X
ICD-9 Finland
Disorders of adrenal glands, Cushing's syndrome[SYNDROMA CUSHING NUD]
+∞
17.9
17
*
A10AB05
ATC
insulin aspart; parenteral (insulins and analog. for injection, fast-acting)
5.5
17.8
55
115
E87.6
ICD-10 Finland
Hypokalaemia
9.8
17.4
35
39
C03CA01
ATC
furosemide; systemic
3.0
17.0
123
534
E21.09
ICD-10 Finland
Other primary hyperparathyroidism
+∞
16.8
16
*
2550B
ICD-9 Finland
Disorders of adrenal glands, Cushing's syndrome[SYNDROMA CUSHING E HYPERFUNCTIO GLAN SUPRARENALI]
+∞
16.8
16
*
E23.00
ICD-10 Finland
Panhypopituitarism
+∞
15.7
15
*
E27.1
ICD-10 Finland
Primary adrenocortical insufficiency
+∞
15.7
15
*
A49.9
ICD-10 Finland
Bacterial infection, unspecified
4.4
15.5
59
153
JN4BD
NOMESCO Finland
Extensive body CT
4.0
15.5
66
191
BCA41
NOMESCO Finland
Endoscopic bilateral adrenalectomy
+∞
14.7
14
*
BC1CD
NOMESCO Finland
Very extensive CT of adrenal glands
+∞
14.7
14
*
215
Kela drug reimbursment
Diabetes, non-insulin-treated
2.8
14.6
116
525
BC1AD
NOMESCO Finland
CT of adrenal glands
28.5
14.4
19
7
H03AA01
ATC
levothyroxine sodium; systemic
2.7
13.9
121
575
A10AC01
ATC
insulin (human); parenteral (insulins and analog. for injection, intermediate-acting)
4.7
13.8
48
114
WX408
NOMESCO Finland
General anesthesy, balanced
2.6
13.7
130
650
C74.0
ICD-10 Finland
Malignant neoplasm: Cortex of adrenal gland
+∞
13.6
13
*
E24
ICD-10 Finland
Cushing syndrome
+∞
13.6
13
*
AA4CM
NOMESCO Finland
Extensive MRI examination of sella turcica with 3 Tesla magnet
+∞
13.6
13
*
E26.0
ICD-10 Finland
Primary hyperaldosteronism
+∞
13.6
13
*
A09
ICD-10 Finland
Other gastroenteritis and colitis of infectious and unspecified origin
3.0
13.4
88
352
R10.4
ICD-10 Finland
Other and unspecified abdominal pain
2.4
13.3
154
854
WX700
NOMESCO Finland
Respiratory and circulatory monitoring
3.1
13.3
81
308
205
Kela drug reimbursment
Chronic hypertension
2.7
13.1
110
512
E11.9
ICD-10 Finland
Type 2 diabetes mellitus, without complications
2.7
12.8
102
458
E28.2
ICD-10 Finland
Polycystic ovarian syndrome
+∞
12.6
12
*
E23.03
ICD-10 Finland
Lack of ACTH
+∞
12.6
12
*
E27.0
ICD-10 Finland
Other adrenocortical overactivity
+∞
12.6
12
*
I10
ICD-10 Finland
Essential (primary) hypertension
2.2
12.0
207
1364
R53
ICD-10 Finland
Malaise and fatigue
2.7
11.8
95
428
2533
FHL
Unilateral removal of additional egg
+∞
11.5
11
*
E34.9
ICD-10 Finland
Endocrine disorder, unspecified
+∞
11.5
11
*
L01XX23
ATC
mitotane; oral
+∞
11.5
11
*
A10BA02
ATC
metformin; oral
2.4
11.4
117
600
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
2.4
11.3
120
626
C07AB07
ATC
bisoprolol; oral
2.2
11.2
173
1073
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
3.0
10.8
66
251
E24.4
ICD-10 Finland
Alcohol-induced pseudo-Cushing syndrome
+∞
10.5
10
*
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
3.0
10.3
65
248
A02BC02
ATC
pantoprazole; systemic
2.1
10.0
245
1812
TPH07
NOMESCO Finland
Cathetrisation of artery
3.3
9.9
51
171
JN3BD
NOMESCO Finland
Extensive abdominal CT
3.2
9.9
55
194
JN3CD
NOMESCO Finland
Abdominal CT examination both without and with contrast
6.7
9.7
24
38
Z71.3
ICD-10 Finland
Dietary counselling and surveillance
4.3
9.7
35
87
J01MA12
ATC
levofloxacin; systemic
2.5
9.5
83
387
E27.3
ICD-10 Finland
Drug-induced adrenocortical insufficiency
+∞
9.4
9
*
2550C
ICD-9 Finland
Disorders of adrenal glands, Cushing's syndrome[SYNDROMA CUSHING E HYPERSECRETIO HYPOFYSEOS]
+∞
9.4
9
*
L28
ICPC
Limited function/disability (L)
2.8
9.4
65
266
JN1AE
NOMESCO Finland
Ultrasound examination of upper part of abdomen
3.3
9.3
48
162
DM1AA
NOMESCO Finland
Paranasal sinuses X-ray examination without contrast
5.9
9.2
25
45
TPH04
NOMESCO Finland
Cathetrisation of vein
2.4
9.2
90
443
N04BC06
ATC
cabergoline; oral (dopamine agonists)
37.7
9.1
11
*
FB1BD
NOMESCO Finland
Extensive CT examination of arteria pulmonalis
3.5
9.0
42
131
I26.9
ICD-10 Finland
Pulmonary embolism without mention of acute cor pulmonale
4.6
9.0
30
69
B01AB05
ATC
enoxaparin; parenteral
2.1
8.9
123
710
N91.1
ICD-10 Finland
Secondary amenorrhoea
11.1
8.9
16
15
E13.9
ICD-10 Finland
Other specified diabetes mellitus, without complications
14.5
8.8
14
10
DM1QA
NOMESCO Finland
Paranasal sinuses X-ray examination in one projection
4.8
8.7
28
62
R4110
NOMESCO Finland
Physiotherapy
2.1
8.5
113
638
N02BE01
ATC
paracetamol; systemic, rectal
2.4
8.5
311
2619
I15.2
ICD-10 Finland
Hypertension secondary to endocrine disorders
92.1
8.4
9
*
E21.3
ICD-10 Finland
Hyperparathyroidism, unspecified
92.1
8.4
9
*
102
Kela drug reimbursment
Diabetes insipidus
+∞
8.4
8
*
H01AC01
ATC
somatropin; parenteral
+∞
8.4
8
*
E24.1
ICD-10 Finland
Nelson syndrome
+∞
8.4
8
*
B01AB10
ATC
tinzaparin; parenteral
3.8
8.2
34
96
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
2.6
8.2
63
273
ZXC86
NOMESCO Finland
Use of endoscopic device
22.6
8.1
11
5
N02AJ06
ATC
codeine and paracetamol; systemic
2.0
8.1
143
903
SPAT1250
SPAT
Comprehensive monitoring of chronic illness
2.1
8.0
105
589
TPH15
NOMESCO Finland
Insertion of central venous catheter through external or internal jugular vein
3.9
8.0
32
88
A03FA01
ATC
metoclopramide; systemic, rectal
2.2
7.9
90
472
SPAT1262
SPAT
Handing over of treatment supplies
2.3
7.9
82
412
XF400
NOMESCO Finland
ECG with 12 standard connections
2.4
7.8
67
308
C08CA13
ATC
lercanidipine; oral
2.7
7.8
55
226
J01FF01
ATC
clindamycin; systemic
2.0
7.7
113
661
ZX120
NOMESCO Finland
Intravenous
3.0
7.7
45
165
E66.01
ICD-10 Finland
Obesity due to excess calories
2.9
7.7
47
175
R60.0
ICD-10 Finland
Localized oedema
2.8
7.7
49
191
E66.8
ICD-10 Finland
Other obesity
3.7
7.6
32
92
N02AX02
ATC
tramadol; systemic, rectal
1.9
7.5
155
1028
BBA30
NOMESCO Finland
Excision of lesion of parathyroid gland
81.7
7.4
8
*
E21.0
ICD-10 Finland
Primary hyperparathyroidism
81.7
7.4
8
*
A28
ICPC
Limited function/disability NOS
2.7
7.4
53
219
E87.1
ICD-10 Finland
Hypo-osmolality and hyponatraemia
4.7
7.4
24
54
G03BA03
ATC
testosterone; systemic, rectal, sublingual, transdermal
5.1
7.4
22
45
M80.0
ICD-10 Finland
Postmenopausal osteoporosis with pathological fracture
9.7
7.3
14
15
301
Kela drug reimbursment
Growth hormone
+∞
7.3
7
*
2273A
ICD-9 Finland
Benign neoplasm of other endocrine glands and related structures, Pituitary gland and craniopharyngeal duct (pouch)
+∞
7.3
7
*
AA4WT
NOMESCO Finland
Selective blood sample from sinus petrosus inferior
+∞
7.3
7
*
N02AA05
ATC
oxycodone; systemic
2.6
7.3
55
234
I15.9
ICD-10 Finland
Secondary hypertension, unspecified
20.5
7.2
10
5
R03BB04
ATC
tiotropium bromide; inhalant
2.9
7.1
44
165
F43.22
ICD-10 Finland
Adaptation disorder with mixed anxiety and depression
4.1
7.0
26
67
NA2AA
NOMESCO Finland
Thoracal spine X-ray examination without contrast
5.7
7.0
19
35
JN1CG
NOMESCO Finland
Extensive MRI examination of upper part of abdomen with high intensity magnet
6.1
7.0
18
31
AA1AD
NOMESCO Finland
CT of head and brain
2.1
7.0
84
451
GD1PA
NOMESCO Finland
X-ray examination of the lungs in one projection
3.1
7.0
37
128
WZC30
NOMESCO Finland
Teaching
2.5
6.9
54
237
J18.9
ICD-10 Finland
Pneumonia, unspecified
2.1
6.9
80
424
A10AB04
ATC
insulin lispro; parenteral (insulins and analog. for injection, fast-acting)
4.3
6.8
24
59
FM1AE
NOMESCO Finland
Standard cardiac ultrasound examination
2.4
6.8
61
287
R50.9
ICD-10 Finland
Fever, unspecified
2.5
6.7
55
246
G47.3
ICD-10 Finland
Sleep apnoea
2.1
6.7
77
405
ZX114
NOMESCO Finland
Intramuscular
8.0
6.7
14
18
TKC20
NOMESCO Finland
Catheterisation of bladder
3.2
6.6
34
115
J45.0
ICD-10 Finland
Predominantly allergic asthma
2.9
6.6
40
151
WX404
NOMESCO Finland
Intravenous generell anesthesy
2.0
6.6
87
485
C09AA05
ATC
ramipril; oral
2.1
6.5
83
456
C79.8
ICD-10 Finland
Secondary malignant neoplasm of other specified sites
5.9
6.5
17
30
N03AX16
ATC
pregabalin; oral
2.0
6.5
93
536
BBA40
NOMESCO Finland
Subtotal parathyroidectomy
71.1
6.4
7
*
E0000UV
ATC
NA
1.8
6.4
149
1015
XF603
NOMESCO Finland
Direct intraarterial blood pressure measurement
4.8
6.4
20
44
J45.9
ICD-10 Finland
Asthma, unspecified
2.1
6.3
72
375
A10AB01
ATC
insulin (human); parenteral (insulins and analog. for injection, fast-acting)
4.5
6.3
21
49
Z00.4
ICD-10 Finland
General psychiatric examination, not elsewhere classified
2.8
6.3
40
154
A02BC03
ATC
lansoprazole; oral
1.9
6.3
104
628
E21.1
ICD-10 Finland
Secondary hyperparathyroidism, not elsewhere classified
+∞
6.3
6
*
E23.04
ICD-10 Finland
Hypogonadotropic hypogonadism
+∞
6.3
6
*
E27.2
ICD-10 Finland
Addisonian crisis
+∞
6.3
6
*
C10AA01
ATC
simvastatin; oral
1.8
6.1
138
925
C10AA05
ATC
atorvastatin; oral
1.8
6.1
119
763
NA3AA
NOMESCO Finland
Lumbar spine X-ray examination without contrast
2.7
6.1
42
169
EP1AE
NOMESCO Finland
Neck ultrasound examination
3.6
6.1
26
77
WX892
NOMESCO Finland
Monitored bed care
2.9
6.1
35
128
WX110
NOMESCO Finland
Local anesthesy
1.8
6.1
246
1977
E78.01
ICD-10 Finland
Pure hypercholesterolaemia
2.1
6.0
72
385
C03AA03
ATC
hydrochlorothiazide; oral
2.8
6.0
38
146
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
229
299
16.37
185.55
8.7
1.7
358.5
364.6
nmol/l
0.09
223
279
68
42
19.26
82.36
1.3
1.1
0.4
—
nmol/l
—
6
0
58
42
15.96
64.32
1.4
1.2
262.2
364.5
pmol/l
0.66
45
36
53
74
8.09
36.93
2.6
1.3
10.6
11.2
u/l
0.09
45
58
282
1531
3.79
34.52
10.2
5.7
1.2
1.2
mmol/l
0.17
232
1291
258
1406
3.31
29.64
8.8
4.9
1.2
1.2
mmol/l
0.36
251
1263
253
1370
3.27
29.25
3.6
2.1
77.2
77.0
nmol/l
0.04
243
1215
246
1319
3.21
28.77
7.2
4.3
33.9
35.9
g/l
5.63
236
1233
77
197
4.59
28.35
2.7
3.3
4.2
4.5
pmol/l
1.44
72
174
67
199
3.84
19.89
2.1
1.4
—
—
—
0
0
104
414
3.04
19.34
2.5
2.1
2.3
2.4
g/l
0.31
95
383
88
320
3.24
19.08
9.3
6.6
0.9
1.2
mmol/l
0.26
74
257
22
23
10.06
18.94
1.5
1.7
—
—
—
0
0
70
222
3.60
18.83
6.3
6.4
9.7
9.0
mmol/l
0.46
70
211
98
389
3.01
18.22
2.7
2.1
19.1
23.5
%
2.29
84
332
73
249
3.36
17.48
4.0
3.5
2.4
2.0
mmol/l
0.33
56
193
278
1861
2.58
17.37
8.0
4.2
7.0
6.6
mmol/l
2.05
265
1733
57
167
3.81
17.17
2.1
1.3
21.3
26.1
iu/l
0.49
48
139
63
201
3.53
16.72
3.5
2.9
94.4
67.6
ng/l
1.95
58
176
105
463
2.71
15.84
2.6
2.1
11.1
13.9
umol/l
3.85
97
424
28
49
6.07
15.61
3.2
1.4
0.2
0.4
nmol/l
0.99
20
40
190
1125
2.30
14.89
4.7
2.8
—
—
—
0
0
164
927
2.29
14.20
4.3
3.9
13.6
8.5
mg/mmol
0.48
114
554
154
866
2.26
13.33
4.2
2.7
0.3
0.5
e6/l
0.87
122
637
23
40
6.04
12.88
1.3
1.4
—
—
—
0
0
138
759
2.24
12.46
2.8
2.0
3.0
3.1
mg/l
0.31
127
649
98
471
2.43
12.06
2.3
1.9
—
—
—
0
0
167
1007
2.12
11.82
3.4
2.4
53.5
56.8
u/l
0.51
154
922
151
878
2.15
11.73
3.2
3.0
1712.3
1009.8
ng/l
0.98
132
745
245
1710
2.10
11.65
8.9
6.1
8.9
10.5
umol/l
3.93
236
1617
265
1931
2.08
10.89
11.6
9.1
5.0
4.0
e9/l
8.15
237
1706
28
72
4.10
10.03
1.2
1.1
—
—
—
0
0
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
29
77
3.98
9.95
2.7
2.1
0.2
0.4
u/ml
2.45
15
38
188
1244
1.96
9.81
2.2
1.9
88.4
97.1
pmol/l
1.95
100
626
106
578
2.13
9.42
5.2
2.8
2.5
2.4
mmol/l
1.08
96
508
326
2632
2.24
9.41
7.0
3.9
15.1
14.6
pmol/l
2.81
313
2394
37
121
3.27
9.35
1.8
2.1
2.0
1.5
g/l
1.65
31
105
319
2558
2.17
9.30
12.0
7.2
83.8
76.5
u/l
1.31
311
2389
215
1510
1.91
9.18
3.7
2.6
129.1
98.4
ug/l
1.31
203
1387
91
475
2.18
9.01
3.7
2.6
2.2
2.9
e6/l
0.49
52
248
69
321
2.39
8.96
2.5
1.9
—
—
—
0
0
68
316
2.39
8.85
2.4
1.8
—
—
—
0
0
26
70
3.90
8.76
1.3
1.5
—
—
—
0
0
127
759
1.98
8.71
2.3
1.7
0.8
1.1
mg/l
1.74
101
583
129
777
1.97
8.64
3.0
2.1
—
—
—
0
0
44
168
2.82
8.52
3.7
3.5
2.5
2.2
mmol/l
0.13
35
129
17
33
5.33
8.48
4.9
1.6
52.7
17.3
ug/l
1.08
17
33
167
1102
1.88
8.46
4.5
3.2
2.4
2.3
mmol/l
0.05
153
963
99
561
2.01
7.79
4.0
3.4
495.8
197.2
ng/l
0.48
80
401
49
209
2.53
7.64
2.3
2.6
214.3
163.2
ng/l
0.51
44
188
(40770918) von Willebrand factor (vWf).activity actual/normal in Platelet poor plasma by Immunoassay
10
12
8.52
7.61
1.7
2.0
168.4
115.9
%
—
10
12
92
512
2.03
7.60
3.6
2.5
0.9
1.0
e6/l
0.15
53
283
306
2497
1.93
7.37
5.7
4.0
15.7
11.3
mm/h
4.02
287
2290
272
2147
1.82
7.19
6.2
4.1
1139.8
140.0
e6/l
—
5
34
20
52
3.99
7.07
3.3
1.9
16.5
16.1
%
0.16
12
23
21
58
3.76
6.84
2.4
3.2
4.2
4.8
e9/l
0.48
21
58
32
116
2.91
6.81
2.5
2.2
—
—
—
0
0
32
116
2.91
6.81
2.5
2.2
8.3
7.5
g/l
0.77
26
90
32
116
2.91
6.81
2.5
2.2
3.7
3.7
g/l
0.01
27
87
27
89
3.18
6.75
1.6
1.3
217.5
305.6
ug/g
1.12
16
52
125
801
1.81
6.65
1.4
1.3
0.8
1.8
u/ml
0.96
33
214
354
3077
2.22
6.64
8.9
5.3
42.5
39.2
mmol/mol
5.90
342
2868
21
60
3.64
6.52
1.3
1.4
—
—
—
0
0
21
60
3.64
6.52
1.3
1.4
—
—
—
0
0
21
60
3.64
6.52
2.8
3.6
58.3
59.3
%
0.12
21
60
37
151
2.60
6.31
1.9
1.8
—
—
—
0
0
6
0
+∞
6.26
1.5
0.0
0.9
—
nmol/l
—
6
0
167
1184
1.70
6.14
3.9
3.5
24.2
31.6
ng/l
0.77
115
790
126
826
1.76
6.14
3.6
2.6
2637.1
7536.8
umol/l
0.99
114
705
206
1546
1.68
6.10
5.6
3.8
—
—
—
0
0
19
54
3.64
5.95
2.5
1.8
128.6
129.7
g/l
0.06
14
39
114
733
1.77
5.91
1.8
1.5
18.7
21.0
nmol/l
1.03
104
613
155
1102
1.66
5.50
3.6
3.0
35.4
30.3
u/l
0.46
141
1048
355
3150
2.05
5.34
7.6
4.7
1.7
1.9
mu/l
1.65
334
2880
15
39
3.96
5.31
1.3
1.2
—
—
—
0
0
58
313
2.00
5.14
4.2
3.1
—
—
—
0
0
100
645
1.73
5.04
1.9
1.7
417.3
13619847.9
pmol/l
0.50
84
536
19
62
3.17
4.85
1.9
1.5
—
—
—
0
0
55
299
1.97
4.77
3.1
2.3
30.6
34.0
u/l
0.31
47
256
63
363
1.87
4.60
4.3
3.0
6.3
7.2
umol/l
0.17
54
315
23
91
2.62
4.21
1.2
1.3
423.1
480.9
mg/l
0.48
23
84
15
47
3.28
4.09
1.4
1.2
40.2
5.3
u/ml
—
5
19
84
546
1.68
4.06
2.1
1.6
1010.2
1177.0
nmol/l
1.05
69
399
27
118
2.38
4.04
2.3
1.8
3.7
3.6
ug/l
0.01
27
108
15
48
3.21
3.97
1.1
1.1
—
—
—
0
0
22
88
2.59
3.95
1.8
1.9
3.5
6.0
iu/l
—
7
30
8
13
6.25
3.51
1.6
3.4
2003.3
681.1
u/ml
—
8
13
365
3366
1.87
3.50
26.3
12.5
22.5
21.9
mg/l
0.13
321
2590
321
2867
1.58
3.42
31.2
15.1
14.1
13.6
%
6.76
316
2821
22
96
2.37
3.33
1.5
1.6
—
212.5
—
0
8
22
96
2.37
3.33
1.2
1.2
—
—
—
0
0
201
1645
1.44
3.27
4.4
3.5
0.0
0.0
estimate
0.50
47
306
16
60
2.74
3.26
1.6
1.6
—
—
—
0
0
199
1627
1.44
3.25
6.2
4.6
0.0
0.0
estimate
0.50
49
317
12
38
3.22
3.24
1.0
1.0
—
—
—
0
0
197
1614
1.43
3.15
4.2
3.4
0.0
0.0
estimate
0.00
51
311
19
80
2.44
3.11
2.0
1.6
—
—
—
0
0
6
8
7.59
3.06
1.0
1.0
—
—
—
0
0
6
8
7.59
3.06
1.0
1.0
99.7
96.4
%
—
6
8
9
21
4.36
3.01
1.3
1.3
1.8
2.0
mmol/l
—
9
21
25
121
2.14
2.99
2.1
1.8
4472.7
3449.0
u/l
—
9
39
12
40
3.06
2.99
1.6
1.9
—
—
—
0
0
11
35
3.20
2.95
1.6
2.0
—
—
—
0
0
24
115
2.16
2.95
1.7
1.6
—
—
—
0
0
44
264
1.75
2.84
1.3
1.3
160.0
140.7
iu/ml
0.10
18
116
52
328
1.67
2.81
1.9
4.1
13.0
19.7
ug/l
0.19
40
274
13
48
2.77
2.74
1.8
1.4
—
—
—
0
0
7
14
5.07
2.74
1.3
1.9
—
—
—
0
0
7
14
5.07
2.74
1.0
1.0
—
—
—
0
0
14
54
2.65
2.73
1.2
1.3
—
—
—
0
0
(3011547) Coagulation factor VII activity actual/normal in Platelet poor plasma by Coagulation assay
6
10
6.07
2.70
1.5
1.0
104.0
116.8
%
—
6
10
346
3195
1.58
2.65
25.2
11.5
82.3
83.1
ml/min/173m2
0.25
313
2585
32
180
1.84
2.56
1.9
1.4
—
—
—
0
0
259
2274
1.39
2.53
4.7
3.1
100.0
44.9
u/l
2.27
247
2126
17
76
2.29
2.47
3.1
2.5
154.0
117.3
ug/min
—
9
44
17
76
2.29
2.47
2.1
1.6
—
—
—
0
0
24
124
1.99
2.46
1.6
1.9
—
—
—
0
0
23
117
2.02
2.46
1.7
1.7
—
—
—
0
0
7
17
4.17
2.37
1.4
2.4
—
—
—
0
0
116
904
1.40
2.33
2.0
1.6
1.6
1.3
mmol/l
1.65
99
760
8
23
3.53
2.28
1.9
3.2
—
—
—
0
0
10
36
2.82
2.21
2.4
4.1
—
—
—
0
0
10
36
2.82
2.21
1.7
1.4
—
—
—
0
0
7
19
3.73
2.16
1.3
3.8
98.3
92.7
%
—
7
19
333
3086
1.45
2.14
27.9
13.1
39.1
40.0
%
0.95
241
2307
8
25
3.24
2.10
1.0
1.1
—
—
—
0
0
84
630
1.42
2.08
1.3
1.3
29.5
33.3
iu/ml
0.08
18
201
23
125
1.89
2.07
2.9
3.3
25.5
1296.2
u/ml
0.60
18
107
53
366
1.52
2.00
36.9
16.5
1.4
1.2
inr
—
7
57
5
11
4.59
1.94
3.2
1.4
—
—
—
0
0
6
16
3.79
1.94
1.0
1.3
—
—
—
0
0
6
16
3.79
1.94
1.0
1.3
—
—
—
0
0
6
17
3.57
1.84
2.0
1.2
—
—
—
0
0
6
17
3.57
1.84
1.0
1.4
—
—
—
0
0
6
17
3.57
1.84
1.0
1.4
—
—
—
0
0
15
73
2.10
1.83
1.5
1.3
—
—
—
0
0
11
47
2.38
1.79
4.6
3.6
0.4
1.5
%
1.78
11
38
151
1275
1.29
1.71
4.8
3.5
—
—
—
0
0
7
25
2.83
1.65
1.0
1.0
—
—
—
0
0
79
611
1.36
1.64
1.3
1.3
1.2
10.7
u/ml
3.99
26
237
20
117
1.75
1.48
2.1
1.9
—
—
—
0
0
110
907
1.29
1.47
4.4
3.7
0.0
0.0
estimate
0.50
49
311
38
263
1.49
1.45
2.5
2.4
—
13.2
—
0
11
11
54
2.07
1.34
1.6
1.1
28.9
13.8
u/l
0.41
11
45
8
35
2.31
1.27
1.4
1.8
—
—
—
0
0
8
35
2.31
1.27
1.4
1.8
—
—
—
0
0
8
35
2.31
1.27
1.4
1.8
—
—
—
0
0
342
3263
1.31
1.18
6.3
4.3
6.3
5.9
mmol/l
3.73
329
2991
5
20
2.52
1.15
1.0
1.1
—
—
—
0
0
15
88
1.73
1.13
1.2
1.2
—
30.2
—
0
10
16
97
1.68
1.08
1.3
1.2
—
—
—
0
0
18
113
1.62
1.07
1.2
1.2
—
1.0
—
0
6
11
60
1.86
1.03
1.5
1.3
—
—
—
0
0
9
47
1.94
1.02
1.3
1.1
—
—
—
0
0
7
37
1.91
0.94
1.0
1.1
—
—
—
0
0
353
3407
1.29
0.91
6.1
4.7
2.7
2.8
mmol/l
1.56
330
3137
6
29
2.08
0.89
1.0
1.2
—
—
—
0
0
6
29
2.08
0.89
1.0
1.2
—
—
—
0
0
240
2235
1.18
0.89
3.4
3.1
—
—
—
0
0
31
230
1.38
0.88
1.8
1.7
—
—
—
0
0
6
30
2.01
0.87
1.0
1.2
—
—
—
0
0
6
30
2.01
0.87
1.0
1.2
—
—
—
0
0
6
30
2.01
0.87
1.0
1.2
—
—
—
0
0
15
97
1.57
0.82
1.3
1.2
—
—
—
0
0
14
90
1.58
0.79
2.1
2.8
—
—
—
0
0
7
39
1.81
0.73
1.1
1.1
—
—
—
0
0
5
26
1.93
0.71
1.8
1.4
—
—
—
0
0
10
61
1.66
0.69
1.2
1.4
—
—
—
0
0
10
155
0.64
0.67
1.5
1.4
—
—
—
0
0
24
180
1.35
0.66
1.6
1.6
—
—
—
0
0
13
87
1.51
0.64
1.7
1.3
—
—
—
0
0
5
29
1.73
0.64
1.6
1.1
—
—
—
0
0
5
30
1.67
0.61
1.6
1.2
—
—
—
0
0
5
30
1.67
0.61
1.2
1.3
—
—
—
0
0
0
21
0.00
0.60
0.0
1.3
—
—
—
0
0
56
654
0.83
0.60
1.5
1.4
—
—
—
0
0
331
3210
1.17
0.58
5.0
3.8
1.6
1.3
mmol/l
5.96
311
2951
6
38
1.59
0.54
2.8
1.6
—
—
—
0
0
342
3334
1.17
0.51
5.6
4.2
1.4
1.5
mmol/l
4.79
323
3073
10
67
1.51
0.50
5.4
4.0
21.4
28.6
mg/l
—
5
43
7
48
1.47
0.47
1.1
1.1
—
—
—
0
0
343
3350
1.16
0.46
5.6
4.2
4.6
4.7
mmol/l
1.86
324
3106
14
103
1.37
0.46
1.1
1.1
—
6.1
—
0
15
11
152
0.72
0.45
1.4
1.9
3.5
2.6
mg/l
0.42
11
108
24
193
1.26
0.44
1.3
1.4
—
—
—
0
0
7
51
1.38
0.44
1.3
1.1
—
—
—
0
0
5
31
1.62
0.43
2.4
1.5
—
—
—
0
0
0
15
0.00
0.41
0.0
1.1
—
1388.3
—
0
15
12
88
1.37
0.40
1.5
1.1
—
—
—
0
0
14
182
0.76
0.40
1.1
1.0
—
—
—
0
0
10
71
1.42
0.39
1.1
1.8
—
—
—
0
0
11
146
0.75
0.36
1.5
1.5
—
—
—
0
0
9
123
0.73
0.35
1.2
1.7
—
—
—
0
0
6
44
1.37
0.34
2.8
1.6
—
—
—
0
0
12
91
1.33
0.34
1.3
1.6
—
—
—
0
0
46
408
1.14
0.33
1.7
1.7
1.6
1.5
%
0.31
33
358
365
3599
1.15
0.31
16.7
9.9
27.6
25.6
u/l
1.21
360
3477
10
75
1.34
0.30
1.2
1.2
—
—
—
0
0
12
93
1.30
0.30
4.4
3.6
3.9
3.8
mmol/l
0.17
12
85
7
56
1.25
0.29
1.6
1.3
—
—
—
0
0
28
321
0.86
0.27
1.8
1.7
—
—
—
0
0
16
133
1.21
0.24
1.3
1.6
—
—
—
0
0
11
87
1.27
0.24
1.4
1.3
—
—
—
0
0
37
410
0.89
0.23
9.4
5.9
—
—
—
0
0
5
39
1.29
0.23
1.0
1.4
—
—
—
0
0
68
728
0.92
0.22
5.9
5.1
2.3
2.6
ug/l
0.15
63
643
55
594
0.91
0.22
5.2
4.3
23.8
20.9
%
0.46
27
288
6
52
1.16
0.19
3.5
1.6
—
—
—
0
0
40
434
0.91
0.18
3.5
3.0
0.8
0.7
ug/l
0.20
28
288
8
73
1.10
0.16
1.0
1.5
—
—
—
0
0
6
76
0.79
0.15
1.7
3.1
15.3
28.0
u/ml
—
6
76
69
725
0.94
0.15
4.8
3.6
1.0
1.0
kg/l
0.35
12
86
71
676
1.06
0.14
1.9
1.5
—
—
—
0
0
29
271
1.08
0.10
2.6
2.5
62.2
69.7
ml/min/173m2
0.30
13
108
5
44
1.14
0.10
2.6
1.6
—
—
—
0
0
6
55
1.09
0.09
1.7
1.3
—
—
—
0
0
6
55
1.09
0.09
1.7
1.3
—
—
—
0
0
6
55
1.09
0.09
1.7
1.3
—
—
—
0
0
6
56
1.07
0.08
1.7
1.3
—
—
—
0
0
6
56
1.07
0.08
1.7
1.3
—
—
—
0
0
5
65
0.77
0.08
1.6
1.5
—
—
—
0
0
11
102
1.08
0.03
1.5
1.4
—
—
—
0
0
41
416
0.98
0.00
5.5
4.3
31.0
32.5
%
0.47
31
261
37
368
1.01
0.00
1.8
1.8
—
—
—
0
0
41
412
0.99
0.00
1.8
2.0
—
—
—
0
0
0
9
0.00
0.00
0.0
1.0
—
26.4
—
0
9
0
7
0.00
0.00
0.0
1.6
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.7
—
—
—
0
0
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
0
8
0.00
0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
8
0.00
0.00
0.0
1.5
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint E4_CUSHING and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| E4_CUSHING | 3.602 [2.92, 4.44] | < 0.001 |
| Birth year | 0.996 [0.99, 1.0] | 0.334 |
During the follow-up period (1.1.1998 — 31.12.2019), 240 out of 978 females with E4_CUSHING died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| E4_CUSHING | 3.754 [2.69, 5.23] | < 0.001 |
| Birth year | 0.986 [0.98, 1.0] | 0.003 |
During the follow-up period (1.1.1998 — 31.12.2019), 147 out of 409 males with E4_CUSHING died.
Mortality risk
Mortality risk for people of age
years, who have E4_CUSHING.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.26% | 0.602% |
| 5 | 2.009% | 4.136% |
| 10 | 5.011% | 10.054% |
| 15 | 9.495% | 19.573% |
| 20 | 16.424% | 30.551% |
Relationships between endpoints
↥Index endpoint: E4_CUSHING – Cushing syndrome
GWS hits: 1
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data